USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease." This patent covers HemoShear's core technology which replicates the biology of healthy and diseased human organ systems by applying physiologically-relevant hemodynamic (blood flow) forces and other conditions to organ-specific primary cells.

“Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease.”

"We are very proud of this important milestone in building HemoShear. The issuance of HemoShear's first patent validates the innovation behind our core technology and the strong scientific expertise of our founders, Drs. Brett Blackman and Brian Wamhoff. Physiologically-relevant hemodynamic forces are critical for vascular cell survival and to accurately recreate human biology in the laboratory," said Jim Powers, HemoShear's CEO. "Our technology, in combination with the expertise of our scientists, is the basis for HemoShear's partnerships with pharmaceutical customers aimed at accelerating new drug discovery and reducing risk of failures in their drug research and development efforts."

In addition to the above newly issued patent, the Company has patent applications pending in all major international markets and plans future patent applications for enhancements of the core technology.